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INTRODUCTION
White mulberry (桑白皮 Sāng Bái Pí; Morus alba L.) is 
well known as a traditional Chinese herb for the treatment of 
various diseases and has been approved in China as an anti-
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diabetic herbal drug.[1,2] The earliest report on the property and 
use of folium mori (桑葉 Sāng Yè; FM), leaf of M. alba L., 
appeared in Han dynasty (from 25th to 27th century BC) in the 
Divine Husbandman’s Herbal Foundation Canon (神農本草
經 Shén Nóng Běn Cǎo Jing). Traditional use of FM has been 
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ABSTRACT
Folium mori (桑葉 Sāng Yè, leaf of Morus alba L.; FM) is known to possess hypoglycemic effects, and 1‑deoxynojirimycin (1‑DNJ) 
has been proposed as an important functional compound in FM. However, the hypoglycemic activity of purified 1‑DNJ has been rarely 
studied. It is also not known how FM and 1‑DNJ affect the development of DM nephropathy. This study compared the antidiabetic 
effect of a commercial FM product with that of purified 1‑DNJ in streptozotocin‑induced diabetic rats. Seven days after induction, 
the diabetic rats were gavaged with FM (1, 3, 10, and 30 mg/kg/day), 1‑DNJ (30 mg/kg/day), or vehicle (distilled deionized water; 
2 ml/kg/day) for 7 days. All doses of FM ameliorated fasting and post‑prandial blood glucose concomitantly with an increase in peripheral 
and pancreatic levels of insulin and improved homeostasis model assessment (HOMA‑IR) in diabetic rats in a dose‑dependent manner. 
Increased thiobarbituric acid reactive substances (TBARS) and nitrate/nitrite levels in the kidney, liver, and muscle of diabetic rats were 
reversed by all doses of FM. The renal function of the diabetic rats was normalized by all doses of FM, while blood pressure changes 
were reversed by FM at doses of 3 mg/kg and above. Moreover, most of the above‑mentioned parameters were improved by FM at 
doses of 3 mg/kg and above to a similar extent as that of 1‑DNJ. The results showed superior antidiabetic potential of the commercial 
FM product for glycemic control and protection against the development of diabetic nephropathy.
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to relieve wind‑heat exterior syndrome, to moisten the lung ef-
fectively to relieve cough and lung dryness, to treat dizziness 
and headache caused by liver heat, to remove liver heat to im-
prove eyesight, and to cool blood and stop bleeding. In the late 
16th century, Li Shi‑Zhen (李時珍 Lǐ Shízhēn), a Ming botanist, 
pharmacologist, and the author of the Compendium of Materia 
Medica (本草綱目 Běn Cǎo Gāng Mù), reported FM tea being 
a useful therapy for diabetes. In Taiwan, white mulberry tree is 
cultivated in large areas, and the commercial product of its leaf 
preparation is popular as a complementary/alternative medicine 
for disorders including hyperglycemia, hypertension, and dys-
lipidemia. Recent scientific evidences have confirmed that the 
dried powder, water extract, and ethanol extract of the FM (leaf 
of M. alba L.) possess diverse biological activities, including 
neuroprotective, antimicrobial, antioxidant, anti‑inflammatory, 
anti‑tumor, anti‑atherosclerotic, and hypoglycemic actions.[3]
Diabetes is a common chronic and systemic disorder that 
causes disability and threatens the lives of people worldwide. 
In the field of research on natural products as anti‑diabetic rem-
edies, FM has raised considerable interest. Studies with diabetic 
animals have demonstrated that treatment with FM can acutely or 
chronically lower blood glucose levels in hyperglycemic animals 
and humans.[4‑8] An earlier understanding of the mechanisms that 
underlie FM’s function as a hypoglycemic agent includes its ability 
to curb the desire for food under diabetic conditions,[5] to inhibit 
the activities of intestinal enzymes involved in the digestion of 
carbohydrates,[6] and to inhibit glucose absorption in the small 
intestine.[8] Limited studies on human beings revealed that the 
activities of sucrase and certain enzymes involved in the digestion 
of other disaccharides were largely inhibited by FM,[6] and that in 
control and type 2 diabetes mellitus (DM) patients, co‑ingestion 
of mulberry extract with sucrose significantly reduced the increase 
in postprandial blood glucose levels.[9]
The components of FM that may contribute to its hypoglycemic 
activity have been proposed to be the following: total flavonoids 
as it was found that this fraction is able to inhibit small intestine 
disaccharidases in diabetic rats,[10] polysaccharides as it was 
reported that this fraction is able to scavenge hydroxyl radicals 
and superoxide anion radical in vivo,[11] or iminosugars [i.e. 1‑de-
oxynojirimicin (1‑DNJ)] as it was observed that 1‑DNJ is able 
to inhibit the activity of α‑glucosidase.[12,13] In addition, Hunyadi 
et al. summarized that chlorogenic acid and rutin account for as 
much as half the observed anti‑diabetic activity of FM.[14]
We are fascinated by the idea that 1‑DNJ in FM is an important 
anti‑diabetic com pound, because certain efforts have been made 
by researchers using various approaches to enrich 1‑DNJ in FM 
preparations in order to improve their anti‑diabetic activity.[15‑17] 
Studies on human beings have revealed that a 1‑DNJ–enriched 
FM preparation is an effective hypoglycemic agent in control and 
type 2 DM patients.[9,18] However, a limited number of studies have 
been conducted on the hypoglycemic activity of purified 1‑DNJ in 
diabetic animals.[11,19] From the practical point of view, the ques-
tion that arises in our mind is how important it is to emphasize the 
antidiabetic role of 1‑DNJ in FM if the raw extract of FM already 
possesses significant activity. Consequently, we compared the 
anti‑diabetic activity of FM with that of purified 1‑DNJ. In this 
study, we also aimed to investigate the effect of these FM prepara-
tions on the development of diabetic nephropathy, which, to the 
authors’ knowledge, has not been revealed thus far.
MATERIALS AND METHODS
Plant material and extraction
The spray‑drie d FM (桑葉 Sāng Yè) water extract preparation 
used in this study was kindly provided by Chin Ang Pharmaceutical 
Co., Ltd (Chiayi, Taiwan). Fresh M. alba L. leaves were collected 
from a farm in Chiayi, a county in central Taiwan. One gram of 
the spray‑dried FM water extract preparation was generated from 
10 g of dried white mulberry (桑白皮 Sāng Bái Pí) leaf, and was 
composed of 1.22% 1‑DNJ, according to a high‑performance 
liquid chromatography (HPLC) analysis as described by Ouyang 
et al.,[20] with modifications. Briefly, 1‑DNJ in FM was extracted 
with 0.05 mol/l of HCl and made to react with fluorenylmethoxy-
carbonyl (FMOC)‑Cl at 20°C for 20 min, followed by the addition 
of 0.1 mol/l of glycine and 0.1% acetic acid aqueous solution (v/v). 
After filtration through a 0.45 µm filter, the DNJ–FMOC deriva-
tive in the sample was separated on SUPELCO Ascentis 5‑µm 
C18‑A column (Waters, Milford, MA, USA) at 25°C. The mobile 
phase consisted of acetonitrile: 0.1% aqueous acetic acid (55:45) 
with a flow rate of 1.0 ml/min. The fluorescence detector (Waters 
2475 Multil λ Fluorescence Detector; Waters) was operated at 
λex = 254 nm and λem = 322 nm. The spectrum of HPLC analysis 
of 1‑DNJ standard and of 1‑DNJ in FM extract is shown in Figure 1.
Animals and experimental procedures
Four‑week‑old weanling male Wistar rats were purchased 
from the National Animal Breeding and Research Cen-
ter (Taipei, Taiwan). The animals were maintained under a 12 h 
light–dark cycle at an ambient temperature of 23°C, and were 
given free access to water and standard rat feed (Rodent Diet 
5001; Purina Mills, Richmond, IN, USA). All animals were al-
lowed to adapt to the environment for 1 week after their arrival, 
before beginning the experiment. Diabetes was induced by inject-
ing streptozotocin (Sigma, St Louis, MO, USA) (i.v., 65 mg/kg 
body weight), and the control rats were injected with the same 
volume of vehicle as described by Liu et al.[21] One week after 
the injection, the diabetic animals were randomly assigned to six 
groups which received FM extract (1, 3, 10, or 30 mg/kg body 
weight/day), 1‑DNJ (Tocris Bioscience; Bristol, UK) (30 mg/kg 
body weight/day), or vehicle (distilled and deionized water; 
2 ml/kg body weight/day) by gavage, respectively, for seven con-
secutive days. The control rats received the vehicle only. During the 
experimental period, the animals were housed in metabolic cages 
and were given free access to water and a powdered diet (Rat Diet 
5012; Purina Mills). Food and water intake and urine excretion 
were measured. Li et al. reported that 1‑DNJ was able to improve 
glycemic control in alloxan‑induced diabetic mice at doses of 50 
and 100 mg/kg.[10,11] In the present study, a dose of 30 mg/kg 1‑DNJ 
was used for comparison purposes because our preliminary study 
showed that FM was effective in improving fasting blood glucose 
levels in STZ‑induced diabetic rats in a dose‑dependent manner 
between the doses of 1 and 30 mg/kg.
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The oral glucose tolerance test (OGTT) and blood pressure 
determination of the animals were conducted on days 11 and 
13 after induction, respectively. The animals were then starved 
overnight before they were sacrificed by carbon dioxide euthanasia 
on day 14 after injection. Urine collected during the last 24 h of the 
animal’s life was used to measure creatinine concentrations. Blood 
collected immediately after the animals were sacrificed was used 
to measure the concentrations of glucose, insulin, creatinine, and 
urea nitrogen. At the time the animals were sacrificed, the liver, 
kidney, soleus muscle, extensor digitorum longus muscle, and 
gastrocnemius muscle were isolated and weighed, and the ratio 
of organ tissue to body weight was calculated. Kidney weight 
was defined as the sum of weights of the right and left kidneys 
for each animal. Housing conditions and experimental procedures 
were in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals, and all protocols were approved by the ethi-
cal committee for animal experimentation at Chung Shan Medical 
University, Taichung, Taiwan.
Oral glucose tolerance test
The OGTT was performed by administering a solution of 
10% (w/v) glucose (1 g/kg body weight) by oral gavage. Blood 
samples were withdrawn from the lateral tail vein immediately 
before and 15, 30, 45, 60, 90, and 120 min after the bolus glucose 
loading. Heparin‑containing blood samples were immediately 
centrifuged, and the plasma was separated and frozen at –20°C 
until it was analyzed for glucose and insulin. The area under the 
curve (AUC) of the blood glucose and insulin response to oral 
glucose loading was calculated by the trapezoidal rule.
Systolic blood pressure determination
Systolic blood pressure was determined in the conscious state 
by the indirect tail cuff method using a Model MK‑2000 BP moni-
tor for rats and mice (Muromachi Kikai, Tokyo, Japan) according to 
the manufacturer’s instructions. The measurement was performed 
under room temperature conditions (24°C).
Biochemical analysis of blood and tissue/organ samples
For glucose analysis, plasma was deproteinized and glucose 
concentrations were determined enzymatically.[20] Plasma insulin 
concentration was determined spectrophotometrically with a rat 
insulin enzyme‑linked immunosorbent assay (ELISA) kit ac-
cording to the manufacturer’s instructions. The insulin resistance 
index, as assessed by homeostasis model assessment (HOMA‑IR), 
was calculated to estimate peripheral insulin resistance after 
treatment according to the following formula as described by 
Matthews et al.:
fasting plasma glucose (mg/dl) × fasting plasma insulin 
(µU/ml)/405.[22]
Immediately following the removal of the pancreas, the organ 
was irrigated with cold phosphate buffered saline (PBS) (pH 7.2) 
containing 1 mM phenylmethylsulfonyl fluoride to inhibit protease 
activity and was stored at –80°C until it was assayed for insulin with 
the rat insulin ELISA kit (Mercodia, Uppsala, Sweden) as stated 
above. Immediately following the removal of the liver, gastrocne-
mius muscle, and kidney, the tissues/organs were clamped in liquid 
nitrogen and then stored at –80°C until the lipid peroxidation level 
and nitrate/nitrite content were determined. The lipid peroxidation 
level was determined by measuring thiobarbituric acid reactive 
substances (TBARS) using a fluorescence spectrophotometer (Hi-
tachi F4500; Hitachi Ltd, Tokyo, Japan). The nitrate/nitrite levels 
in the samples were measured spectrophotometrically using the 
nitrate/nitrite kit (Cayman, Ann Arbor, MI, USA) according to the 
manufacturer’s instructions and were analyzed with a micro‑plate 
reader (VersaMax; Molecular Devices Ltd, Sunnyvale, CA, USA). 
Protein assays were performed by using Bio‑Rad protein assay 
kits (Bio‑Rad Laboratories, Richmond, CA, USA).
Creatinine concentrations in the plasma and urine were de-
termined with the Creatinine Reagent Set Kit (Teco Diagnostics, 
Anaheim, CA, USA), and blood urea nitrogen (BUN) was deter-
mined with the QuantiChrom™ Urea Assay Kit (DIUR‑500) (Bio-
Assay Systems, Hayward, CA, USA) according to the manu-
facturer’s instructions. The results were analyzed with the 
micro‑plate reader (VersaMax; Molecular Devices Ltd). Cre-
atinine clearance rate (CCR) was calculated using the standard 
Figure 1. High‑performance liquid chromatography (HPLC) spectrum 
of (A) 1‑DNJ standard, (B) blank, and (C) FM preparation. 1‑DNJ in the 
FM preparation was extracted with 0.05 mol/l HCl, made to react with 
fluorenylmethoxycarbonyl (FMOC)‑Cl to generate the DNJ–FMOC 
derivative, and separated on the SUPELCO Ascentis 5‑μm C18‑A column 
at 25°C. The mobile phase consisted of acetonitrile:0.1% aqueous acetic 
acid (55:45) with a flow rate of 1.0 ml/min. The fluorescence detector was 
operated at λex = 254 nm and λem = 322 nm
C
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formula to determine the capacity of glomerular filtration. The 
glomerular filtration rate (GFR) was also expressed as GFR1 
or GFR2 by dividing the CCR by the kidney weight or body 
weight, respectively.
Histological analysis of glomeruli
Kidneys fixed in 10% neutral buffered formalin were embed-
ded in paraffin, sectioned into 5‑µm sections, and stained with 
hematoxylin and eosin to evaluate the glomerular morphology 
by light microscopy.
Statistical analysis
The data were expressed as mean ± SD. The data were ana-
lyzed by one‑way analysis of variance. Student’s t‑test was used 
to detect differences between the means of the control and diabetic 
groups. Duncan’s multiple comparison test was used to detect dif-
ferences in the means among the STZ‑injected groups. P < 0.05 
were considered statistically significant. All statistical analyses 
were performed with commercially available software (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Animal characteristics
Induction of diabetes with STZ (DM group) was associated 
with the development of a slower rate of body weight gain, greater 
food and water intake, and greater urine excretion [Table 1]. A sig-
nificant muscle loss was also observed in the DM group, suggest-
ing that nitrogen was lost due to a catabolic condition [Table 1]. 
Compared with the DM group, the diabetic rats that received 
treatment with FM (桑葉 Sāng Yè) at a dose of 3 mg/kg and 
above showed significantly improved body weight (P < 0.05). 
The water intake of the diabetic rats was lowered significantly 
by all tested doses of FM (P < 0.05). Similarly, 1‑DNJ elevated 
the body weight and lowered the water intake in diabetic rats. In 
addition, 1‑DNJ significantly reduced the food intake in diabetic 
rats (P < 0.05), which remained unaffected by FM. FM at a dose 
equal to or higher than 3 mg/kg significantly reversed the skeletal 
muscle loss in diabetic rats (P < 0.05). However, 1‑DNJ did not 
show a significant beneficial effect on skeletal muscle loss in 
diabetic rats, compared to FM.
Fasting plasma glucose and plasma and pancreatic insulin 
levels
The STZ injections caused a significantly elevated fasting 
plasma glucose level at day 7 before the first dose of FM or 
1‑DNJ was administered to the diabetic rats (P < 0.05) [Table 2]. 
In the DM group, the fasting plasma glucose level worsened in a 
time‑dependent manner during the 7‑day investigation period. At 
day 11 after the induction of DM, or 4 days after the intervention 
began, 1‑DNJ significantly lowered the fasting plasma glucose 
level by 49.8% compared with the DM group (P < 0.05), while 
FM lowered the fasting plasma glucose level less than that caused 
by 1‑DNJ during the same period. At day 14 after the induction of 
DM, or 7 days after the intervention began, all tested doses of FM 
significantly lowered the fasting plasma glucose level (P < 0.05) 
in a dose‑dependent manner. 1‑DNJ lowered the fasting plasma 
glucose level to a greater extent than FM at day 14, but the ef-
fect was not significantly different compared to that of 3, 10, or 
30 mg/kg FM [Table 2].
The data in Figure 2A show that the pancreatic insulin content 
was significantly lowered in the DM group, but was reversed by FM 
at a dose equal to or greater than 10 mg/kg, and 30 mg/kg 1‑DNJ had 
a similar effect (P < 0.05). The peripheral insulin level showed that 
the DM‑lowered insulin level was significantly alleviated by 1‑DNJ 
and all tested doses of FM [Figure 2B]. The greater fasting insulin 
level in the peripheral blood than in the pancreas of the DM group 
compared to the control group reflected increased insulin secretion 
that was stimulated by the hyperglycemic condition in the DM rats.
The HOMA‑IR calculated using the fasting plasma insulin and 
glucose levels showed that STZ‑induced diabetes caused reduced 
insulin sensitivity compared to the controls (5.73 ± 0.27 for DM vs. 
2.13 ± 0.42 for controls, P < 0.05). While all tested doses of FM signifi-
cantly improved the insulin sensitivity in DM rats in a dose‑dependent 
manner, the HOMA‑IR values for 1, 3, 10, and 30 mg/kg body weight 
FM‑treated DM rats were 3.33 ± 0.40, 2.83 ± 0.76, 2.14 ± 0.34, and 
1.90 ± 0.28, respectively. The HOMA‑IR value of 1‑DNJ–treated DM 
rats was also significantly improved (1.99 ± 0.74).
Oral glucose tolerance test
Blood samples were collected immediately before and during 
the 120‑min period after glucose loading. The responses and the 
integral values of the AUC of plasma glucose during the investiga-
tion period were calculated and are presented in Figure 3A and B, 
respectively. The AUC of glucose was significantly elevated in 
the diabetic group compared to the control group (P < 0.05), and 
Figure 2. Effects of FM and 1‑DNJ on insulin levels in the pancreas 
(A) and peripheral blood (B) of diabetic rats. The data are the mean ± SD 
for six rats in each group. #Significantly different from the control rats 
(P < 0.05). Diabetic groups that do not share the same letter (A, B) are 
significantly different (P < 0.05)
B
A
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this increase was attenuated by treatment with all tested doses 
of FM (P < 0.05). 1‑DNJ also improved the glucose tolerance 
significantly and to an extent similar to that of FM [Figure 3B].
The responses and the integral values of the AUC of plasma 
insulin during the investigation period were calculated and are 
presented in Figure 3C and D, respectively. The AUC of plasma 
insulin during the OGTT period for the DM group was only 
13.0% of the control value [Figure 3D]. However, FM treatment 
at all tested doses significantly improved the insulin response to 
oral glucose loading (P < 0.05) [Figure 3D]. 1‑DNJ showed an 
improved AUC of insulin during the OGTT to an extent similar to 
that of FMat a dose of 3 mg/kg and above (P < 0.05) [Figure 3D].
Table 1: Metabolic characteristics and growth characteristics of control rats or streptozotocin‑induced diabetic rats that did or did not receive FM or 
1‑DNJ*
Control DM DM‑FM1 DM‑FM3 DM‑FM10 DM‑FM30 DM‑DNJ
Body weight (g) 208.7±2.9 153.5±7.0#a 153.6±8.6a 169.2±9.2b 187.8±16.5c 187±5.3c 170.9±12.1b
Food intake (g/24 h) 27.6±1 37.5±1.6#b 36.8±2.2b 36.2±2.1b 35.3±1.6b 35.3±2.0b 32.6±2.1a
Water intake (ml/24 h) 57.0±3.2 211.2±5.4#c 189±8.6b 183.2±6.2ab 170.5±11.1ab 182.2±12.9ab 181±26a
Urine excretion (ml/24 h) 24.3±3.3 147±10.3# 147±13 131.2±10.6 133.8±9.0 136.5±8.2 140.7±26.8
Liver weight/body weight (%) 4.05±0.32 4.54±0.25 4.82±0.46 4.72±0.42 4.30±0.60 4.59±0.27 4.42±0.32
Skeletal muscle weight/body weight (%)† 1.42±0.10 1.11±0.08#a 1.22±0.16ab 1.36±0.10b 1.29±0.09b 1.34±0.09b 1.224±0.10ab
*Values are the mean±SD for six rats per group. DM: Vehicle‑treated diabetic rats; DM‑FM1, DM‑FM3, DM‑ML10, and DM‑FM30: Diabetic rats 
treated with 1, 3, 10, and 30 mg FM/kg body weight, respectively; DM‑DNJ: Diabetic rats treated with 30 mg 1‑DNJ/kg body weight. †Sum of soleus, 
gastrocnemius, and extensor digitorum longus EDL muscles. #Significant difference between the control group and the DM group (P<0.05). Diabetic groups 
that do not share the same letter (a, b, c) are significantly different (P<0.05)
Table 2: Fasting blood glucose concentration of control rats or streptozotocin‑induced diabetic rats that did or did not receive FM or 1‑DNJ during 
the treatment period from day 7 through day 14 after induction*
Time after 
induction
Fasting plasma glucose (mg/dl)
Control DM DM‑FM1 DM‑FM3 DM‑FM10 DM‑FM30 DM‑DNJ
Day 7† 94.2±3.0 260.2±72.7 254.0±50.3 251.0±81.6 266.3±42.8 253.0±79.7 250.2±75.9
Day 11 109.2±6.9 292.5±43.7#a 225.5±84.1a 174.0±33.7ab 168.9±47.3ab 162.2±31.4ab 146.8±45.3b
Day 14 91.3±14.3 368.5±59.1#c 224.0±28.5b 172.2±65.6a 157.8±23.8a 155.2±11.7a 135.5±32.8a
*Values are the mean±SD for six rats per group. †Determined before the intervention with FM or 1‑DNJ was conducted. DM: Vehicle‑treated diabetic rats; 
DM‑FM1, DM‑FM3, DM‑FM10, and DM‑FM30: Diabetic rats treated with 1, 3, 10, and 30 mg FM/kg body weight, respectively; DM‑DNJ: Diabetic rats 
treated with 30 mg 1‑DNJ/kg body weight. #Significant difference between the control and DM groups (P<0.05). Diabetic groups that do not share the same 
letter (a, b, c) are significantly different (P<0.05)
Figure 3. Effects of FM and 1‑DNJ on the plasma glucose as a function of time (A), AUC of plasma glucose (B), plasma insulin as a function of time 
(C), and AUC of plasma insulin (D) in response to an oral glucose bolus (1 g/kg body weight) in diabetic rats. The data in (B) and (D) are the increment 
of glucose and insulin which are being calculated from the AUCs of (A) and (C), respectively. The data are the mean ± SD for six rats in each group. 
#Significantly different from the control (P < 0.05). Diabetic groups that do not share the same letter (A, B, C) are significantly different (P < 0.05)
DC
BA
Huang, et al.: / Journal of Traditional and Complementary Medicine 4 (2014) 162‑170
167
Oxidative stress and inflammation indices in organs/tissues
Compared with the levels in controls rats, lipid peroxidation (as 
measured by the levels of TBARS) was significantly higher in 
the liver, skeletal muscle, and kidney in the DM group (P < 0.05) 
[Figure 4A]. Treatment with FM significantly reversed the el-
evated lipid peroxidation in these tissues/organs (P < 0.05), and 
this reversal occurred in a dose‑dependent manner. 1‑DNJ also 
significantly alleviated the level of lipid peroxidation in these 
tissues/organs in the DM group; however, the effect occurred to 
a lesser extent, especially in skeletal muscle, compared with the 
same dose (30 mg/kg) of FM [Figure 4A].
However, STZ‑induced diabetes significantly elevated the 
nitrate/nitrite content in the liver, skeletal muscle, and kidney, 
compared with the control rats (P < 0.05) [Figure 4B], and the 
levels were all significantly suppressed by treatment with FM and 
1‑DNJ [Figure 4B].
Renal function
As shown in Table 3, the higher kidney weight to body weight 
ratio in the vehicle‑treated diabetic animals than in the controls 
indicated the development of kidney hypertrophy in the diabetic 
animals (P < 0.05). The CCR was 90.2% higher and the BUN 
level was 173.2% higher in the vehicle‑treated diabetic animals 
than in the controls [Table 3]. The GFR that was calculated based 
on kidney weight demonstrated higher values compared with 
the control rats (P < 0.05), suggesting that the glomeruli of the 
DM group were undergoing a hyperfiltration period. The BUN 
level was also significantly higher in the DM group than in the 
controls (P < 0.05), which may reflect both a renal problem and a 
muscle wasting condition in diabetes. FM significantly improved 
the kidney hypertrophy, GFR, and BUN in the diabetic animals 
at a dose of 1 mg/kg and above [Table 3]. 1‑DNJ ameliorated 
the kidney hypertrophy, CCR, and GFR more than that caused 
by same dose (30 mg/kg) of FM. Blood pressure was elevated 
by 51.4% in the DM group compared with the controls, but was 
lowered significantly by FM at 10 and 30 mg/kg by 27.8% and 
25.6%, respectively. 1‑DNJ lowered the blood pressure in dia-
betic rats by 39.5%, which was more than the effect produced 
by FM [Table 3].
Glomerular morphology
The present study collected the kidney for the morphologi-
cal investigation as well as renal function at the time when the 
rats were induced to be diabetes for 2 weeks; therefore, the de-
velopment of diabetic nephropathy was most likely at its initial 
stages. Compared with the normal glomerular morphology in the 
controls [Figure 5], the renal histology of the DM group showed 
signs of pathological changes, such as greater basal membrane 
thickness (reflected by a less transparent basement) and higher 
density of mesangial cells (prominent glomerular hypercellularity) 
that represents moderate proliferation of these cells. However, the 
morphology of the glomerulus was improved by FM treatment. 
We observed that the area of basal membrane thickness and the 
glomerular cellularity were slightly reduced by 1 and 3 mg/kg 
FM, and were largely reduced by 10 and 30 mg/kg FM. 1‑DNJ 
also reversed the renal morphology, and the basal membrane 
thickness and glomerular cellularity were similar to those of the 
controls [Figure 5].
Table 3: * Ratio of kidney weight to body weight (KW/BW), blood urea nitrogen (BUN), creatinine clearance rate (CCR), glomerular filtration 
rate (GFR), and blood pressure (BP) for control rats and rats with streptozotocin‑induced diabetes that did or did not receive FM or 1‑DNJ
Control DM DM‑FM1 DM‑FM3 DM‑FM10 DM‑FM30 DM‑DNJ
KW/BW (%) 0.89±0.04 1.38±0.12#d 1.27±0.09bcd 1.28±0.09cd 1.10±0.09a 1.22±0.06abc 1.14±0.11ab
BUN (mg/dl) 16.4±2.6 44.8±8#c 31.8±11b 27.6±3.2ab 25.1±5.6ab 25±3.7ab 20.8±2.3a
CCR (ml/min) 0.51±0.23 0.97±0.43#b 0.59±0.25a 0.62±0.23a 0.56±0.21a 0.58±0.32a 0.43±0.05a
GFR (CCR/KW) 0.27±0.12 0.51±0.11#b 0.3±0.13a 0.3±0.11a 0.27±0.1a 0.27±0.15a 0.22±0.02a
BP 114.8±7.1 173.8±10.8#a 154.9±35.5ab 139.3±22.9ab 125.4±20.4b 129.3±28.4b 105.2±23.9b
*Values are the mean±SD for six rats per group. DM: Vehicle‑treated diabetic rats; DM‑FM1, DM‑FM3, DM‑FM10, and DM‑FM30: Diabetic rats treated 
with 1, 3, 10, and 30 mg FM/kg body weight, respectively; DM‑DNJ: Diabetic rats treated with 30 mg 1‑DNJ/kg body weight. #Significant difference 
between the control and DM groups (P<0.05). Diabetic groups that do not share the same letter (a, b, c, d) are significantly different (P<0.05), KW/BW: Kidney 
weight to body weight; BUN: Blood urea nitrogen; CCR: Creatinine clearance rate; GFR: Glomerular filtration rate; BP: Blood pressure
Figure 4. Effects of FM and 1‑DNJ on lipid peroxidation (A) and nitrate/
nitrite content in various tissues/organs (B) in diabetic rats. The data are 
the mean ± SD for six rats in each group. #Significantly different from 
the control (P < 0.05). Diabetic groups that do not share the same letter 
(A, B) are significantly different (P < 0.05)
B
A
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DISCUSSION
Various forms of FM (桑葉 Sāng Yè) products are ben-
eficial for glycemic control in diabetic animals and diabetic 
patients.[4‑8] The published data have shown that the effective 
doses of FM extract for glycemic control and reducing the 
blood pressure in diabetic animals were equivalent to a dose of 
500‑1000 mg/kg/day of dried leaf, but not to 250 mg/kg/day, 
in STZ‑induced diabetic rats.[23,24] Among the proposed hypo-
glycemic FM components, 1‑DNJ is one of the mostly studied 
compounds due to its α‑glucosidase inhibitory role which is well 
established.[16,25] Subsequently, a great effort has been made to 
improve the yield of 1‑DNJ from natural resources such as the 
mulberry leaf and other microorganisms.[17] The present study 
reported the anti‑diabetic activity of a commercial FM product 
to be effective at a dose as low as 1 mg/kg, which is equivalent 
to 10 mg/kg dried white mulberry (桑白皮 Sāng Bái Pí) leaf and 
is a much lower dose than what has been previously reported. 
When comparing the anti‑diabetic effect of FM and purified 
1‑DNJ, the FM extract appeared to restore glycemic control and 
renal function in STZ‑induced diabetic rats in a dose‑dependent 
manner and functioned similar to that of purified 1‑DNJ when 
administered at the same dose (30 mg/kg) or even at lower 
doses (1‑10 mg/kg). Moreover, our data also implicated certain 
differential advantages between FM and 1‑DNJ when applied 
as anti‑diabetic agents.
In addition to 1‑DNJ, various components in FM have been 
shown to possess hypoglycemic activity, including flavonoids,[14] 
polysaccharides,[11,14] chlorogenic acid, and rutin.[14] Hunyadi et al. 
reported that chlorogenic acid and rutin account for as much as half 
the observed anti‑diabetic activity of FM.[14] Thus, the hypoglyce-
mic activity of FM found in the present study may be a combined 
effect of these compounds. However, 1‑DNJ has been demon-
strated to improve the glycemic control in alloxan‑induced diabetic 
mice at doses of 50 and 100 mg/kg and in STZ‑induced diabetic 
rats at a dose of 50 mg/kg.[11,19] The present study demonstrated 
the effectiveness of 1‑DNJ as an anti‑diabetic agent at a dose of 
30 mg/kg, which is lower than what has been previously reported. 
Another novel finding of the present study is that despite the fact 
that 1‑DNJ lowered fasting blood glucose to a greater extent than 
the same dose of FM, the latter improved body weight and skeletal 
muscle weight to a greater extent than the former, suggesting an 
overall beneficial effect of FM on energy metabolism.
FM is composed of flavonoids that are known for their antioxi-
dant and anti‑inflammatory activities, such as quercetin‑3‑(6‑mal-
onylglucoside), quercetin, rutin, and β‑carotene.[2,3] Thus, FM 
may be beneficial in DM patients as it can prevent the glucose 
toxicity that is attributed to DM progression and the development 
of complications. Aqueous fractions of FM were able to reverse 
the tumor necrosis factor (TNF)‑α–induced activation of nuclear 
factor‑kappaB and the phosphorylation of an inhibitory factor of 
NF‑kappaB‑α in a time‑ and concentration‑dependent manner.[26] 
FM has been demonstrated to ameliorate the blood glucose level 
in db/db mice, in association with decreased expression of pro‑in-
flammatory cytokines in the adipose tissue and decreased levels 
of lipid peroxides in the adipose tissue and liver.[27] Naowaboot 
et al. reported that the administration of an ethanolic extract of 
FM decreased blood glucose; lowered lipid peroxidation in the 
liver, kidney, heart, and aorta; and restored vascular reactivity 
in STZ‑induced diabetic rats.[23,24] FM has also been reported to 
suppress resistin‑induced human endothelial activation partly via 
antioxidant mechanisms.[28] A polysaccharide fraction of FM was 
shown to scavenge hydroxyl radicals and superoxide anion radi-
cal effects in vitro and could protect alloxan‑induced pancreatic 
islets from damage by scavenging the free radicals and repairing 
the destroyed pancreatic β‑cells.[11] Consistent with these previous 
findings, the present study found that FM dramatically lowered 
the level of lipid peroxidation and NO content in the liver, skeletal 
muscle, and kidney. Further, it was observed in the present study 
that the antioxidant and anti‑inflammatory effects of FM were 
associated with improved insulin sensitivity and renal function in 
STZ‑induced diabetic rats. However, we found that 1‑DNJ also 
significantly lowered the level of lipid peroxidation and NO in 
these tissues/organs, although to a lesser extent than the same dose 
of FM. No reports have indicated a direct antioxidant or anti‑in-
flammatory role for 1‑DNJ; however, these results can be explained 
as being at least partly due to the amelioration of blood glucose 
through 1‑DNJ’s known inhibitory effect on α‑glucosidase. To our 
knowledge, this report is the first to demonstrate the antioxidant 
and anti‑inflammatory roles of 1‑DNJ in diabetes. This result war-
rants further investigation into the regulatory role of this compound 
on antioxidant and immune systems.
The kidney has become the focus of investigation in studies 
on diabetic complications because many of the same factors are 
involved in the development of diabetic nephropathy and other 
common diabetic complications such as microvascular disease and 
retinopathy. The early clinical course of diabetic nephropathy in-
cludes an initial increase in the GFR that correlates with hypertrophy, 
and thus an increased filtration surface of the glomeruli.[29,30] Such 
dysfunction of the kidney can also be reflected by the histological 
characteristics of early diabetic nephropathy, including mesangial 
expansion, diffuse glomerular basement membrane thickening, 
and increased mesangial cellularity.[31] In the present study, renal 
Figure 5. Histological examination showing the effect of FM and 1‑DNJ 
on kidney. Cross sections of glomeruli were stained with hematoxylin and 
eosin (original magnification×100)
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hypertrophy and hyperfiltration in DM rats occurred at the end of 
2 weeks, but were reversed by treatment with FM. The hypogly-
cemic effect of FM may at least partially explain the ameliorated 
renal function in the FM‑treated diabetic rats. However, because 
systemic hypertension also contributes to the development of dia-
betic nephropathy via associated glomerular hypertension,[32] we 
cannot exclude the possibility that FM may benefit renal function 
in diabetes by lowering the blood pressure. Interestingly, we found 
that the blood pressure of diabetic rats was significantly lowered 
by FM only at a dose of 10 mg/kg and above. Nevertheless, FM 
dramatically improved the GFR at a dose as low as 1 mg/kg, sug-
gesting that the protective effect of FM on renal function is mainly 
via its activity rather than by lowering the blood pressure at lower 
doses (e.g. FM dramatically improved blood glucose control and 
oxidative and inflammatory conditions in the kidney). However, we 
found that 1‑DNJ improved the GFR concomitantly with lowered 
blood pressure to a similar extent as the same dose of FM. Although 
the improved renal function by 1‑DNJ and high doses of FM may 
be at least partly due to the improved glycemic control, the role of 
the blood pressure regulatory effect of 1‑DNJ and higher doses of 
FM may not be excluded and warrants further investigation.
CONCLUSION
In conclusion, the present study demonstrated that a com-
mercial FM product possesses hypoglycemic activity similar to 
that of same dose of purified 1‑DNJ, and this effect is associated 
with improved insulin secretion and insulin sensitivity in diabetic 
animals. The present study demonstrated the renoprotective effect 
of both FM and 1‑DNJ in diabetes for the first time and provided 
data for the possible role of these two white mulberry (桑白皮 Sāng 
Bái Pí) preparations in regulating blood pressure. The anti‑diabetic 
effects of both FM and 1‑DNJ are associated with alleviated 
oxidative stress and inflammatory conditions in diabetic animals.
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